Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe

The CYP2C9 enzyme metabolizes a wide range of relevant drugs, among which are oral anticoagulants. VKORC1 is the pharmacodynamic target of the oral anticoagulants. The genetic polymorphisms CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A are the major determinants of the inter-individual variability in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzoianu, Anca D, Trifa, Adrian P, Mureşanu, Dafin F, Crişan, Sorin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393720/
https://www.ncbi.nlm.nih.gov/pubmed/22863573
http://dx.doi.org/10.1111/j.1582-4934.2012.01606.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393720/
https://www.ncbi.nlm.nih.gov/pubmed/22863573
http://dx.doi.org/10.1111/j.1582-4934.2012.01606.x

Ejemplares similares